Results 71 to 80 of about 14,789 (299)

A Randomized Single Blind Parallel Group Study Comparing Monoherbal Formulation Containing Holarrhena antidysenterica Extract with Mesalamine in Chronic Ulcerative Colitis Patients

Ancient Science of Life, 2016
Background: Incidences of side effects and relapses are very common in chronic ulcerative colitis patients after termination of the treatment. Aims and Objectives: This study aims to compare the treatment with monoherbal formulation of Holarrhena ...
Sarika Johari, Tejal Gandhi
doaj   +1 more source

Ocular facial myositis and sialadenitis presenting with new onset ulcerative colitis

JPGN Reports, EarlyView.
Abstract Extra‐intestinal manifestations of inflammatory bowel disease (IBD) can involve most organ systems, although the immunologic underpinnings are not well understood. Most patients who present with an extra‐intestinal manifestation have a single site of extra‐intestinal involvement; however, a small cohort presents with multiple different sites ...
Nicole Du, Nicole Mendez, Anil Darbari
wiley   +1 more source

Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database

BMC Gastroenterology, 2013
Background Although high non-adherence to medication has been noticed for ulcerative colitis (UC), little is known about adherence to mesalamine treatments and determinants that can predict adherence.
Lachaine Jean, Yen Linnette, Beauchemin Catherine, Hodgkins Paul   +3 more
doaj   +1 more source

Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis [PDF]

, 2016
BACKGROUND: Microbial translocation (MT) is a shared feature of HIV infection and inflammatory bowel disease (IBD). AIMS: This study was conducted to assess the impact of IBD (and particularly ulcerative colitis, UC) on plasma markers of MT ...
Alessandra Fantauzzi, Caterina Fimiani, Chiara Pasquale, Clementina Maria Galluzzo, Gabriella d’Ettorre, Ivano Mezzaroma, Lucia Palmisano, Manuela Gatto, Manuela Merli, Marina Franco, Massimo Sanchez, Roberta Amici, Silvia Baroncelli, Vincenzo Vullo, Zuleika Michelini   +14 more
core   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

Clinical Pharmacology: Advances and Applications, 2019
Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg ...
Jakate A, McNamee B, Burkindine D
doaj  

Differential diagnosis problem of pulmonary changes in ulcerative colitis [PDF]

Vojnosanitetski Pregled, 2010
Introduction. Inflammatory intestinal diseases are often accompanied with extraintestinal and even pulmonary manifestations. The treatment of these intestinal diseases includes sulphasalazine and mesalazine, which may have undesirable allergic and other ...
Đurić Mirna, Považan Đorđe, Sečen Svetozar, Jović Jelena   +3 more
doaj   +1 more source

Single‐center experience of the Crohn's disease exclusion diet in the United States: A retrospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background The Crohn's Disease Exclusion Diet (CDED) offers a dietary means of inducing and maintaining remission for patients with Crohn's disease (CD). Descriptions of efficacy have emerged primarily from Israel, Europe, and Canada. Here, we offer real‐world experience, from a tertiary care center in the United States. Methods We conducted a
Mayah Greenfield, Caroline Salozzo, Wenya Chen, Jennifer Strople, Jeffrey Brown, Joseph Runde   +5 more
wiley   +1 more source

Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial

Journal of Clinical Medicine, 2021
Background and Aims: Ulcerative colitis (UC) is a chronic inflammatory disease. Fecal microbial transplantation (FMT) is a promising alternative treatment.
J. Březina, L. Bajer, P. Wohl, D. Ďuricová, P. Hrabák, A. Novotný, J. Koželuhová, M. Lukáš, J. Mrázek, K. Fliegerová, S. Kvasnová, Mekadim Chahrazed, J. Mareš, J. Spicak, P. Drastich   +14 more
semanticscholar   +1 more source

Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini, Hassan Valadbeigi, Seyedeh Mahdieh Khoshnazar, Saeed Khoshnood, Shahab Falahi, Delsuz Rezaee, Ali Hematian, Mohammad Hossein Haddadi   +7 more
wiley   +1 more source